These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 23901094)

  • 1. Daily acyclovir to decrease herpes simplex virus type 2 (HSV-2) transmission from HSV-2/HIV-1 coinfected persons: a randomized controlled trial.
    Mujugira A; Magaret AS; Celum C; Baeten JM; Lingappa JR; Morrow RA; Fife KH; Delany-Moretlwe S; de Bruyn G; Bukusi EA; Karita E; Kapiga S; Corey L; Wald A;
    J Infect Dis; 2013 Nov; 208(9):1366-74. PubMed ID: 23901094
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acyclovir and transmission of HIV-1 from persons infected with HIV-1 and HSV-2.
    Celum C; Wald A; Lingappa JR; Magaret AS; Wang RS; Mugo N; Mujugira A; Baeten JM; Mullins JI; Hughes JP; Bukusi EA; Cohen CR; Katabira E; Ronald A; Kiarie J; Farquhar C; Stewart GJ; Makhema J; Essex M; Were E; Fife KH; de Bruyn G; Gray GE; McIntyre JA; Manongi R; Kapiga S; Coetzee D; Allen S; Inambao M; Kayitenkore K; Karita E; Kanweka W; Delany S; Rees H; Vwalika B; Stevens W; Campbell MS; Thomas KK; Coombs RW; Morrow R; Whittington WL; McElrath MJ; Barnes L; Ridzon R; Corey L;
    N Engl J Med; 2010 Feb; 362(5):427-39. PubMed ID: 20089951
    [TBL] [Abstract][Full Text] [Related]  

  • 3. High-dose valacyclovir decreases plasma HIV-1 RNA more than standard-dose acyclovir in persons coinfected with HIV-1 and HSV-2: a randomized crossover trial.
    Perti T; Saracino M; Baeten JM; Johnston C; Diem K; Ocbamichael N; Huang ML; Selke S; Magaret A; Corey L; Wald A
    J Acquir Immune Defic Syndr; 2013 Jun; 63(2):201-8. PubMed ID: 23542637
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characteristics of HIV-1 discordant couples enrolled in a trial of HSV-2 suppression to reduce HIV-1 transmission: the partners study.
    Lingappa JR; Kahle E; Mugo N; Mujugira A; Magaret A; Baeten J; Bukusi EA; Cohen CR; Katabira E; Ronald A; Kiarie J; Farquhar C; Stewart GJ; Makhema J; Essex M; Were E; Fife K; Debruyn G; Gray G; McIntyre J; Manongi R; Kapiga S; Coetzee D; Allen S; Inambao M; Kayitenkore K; Karita E; Kanweka W; Delany S; Rees H; Vwalika B; Coombs RW; Morrow R; Whittington W; Corey L; Wald A; Celum C;
    PLoS One; 2009; 4(4):e5272. PubMed ID: 19404392
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Once-daily valacyclovir to reduce the risk of transmission of genital herpes.
    Corey L; Wald A; Patel R; Sacks SL; Tyring SK; Warren T; Douglas JM; Paavonen J; Morrow RA; Beutner KR; Stratchounsky LS; Mertz G; Keene ON; Watson HA; Tait D; Vargas-Cortes M;
    N Engl J Med; 2004 Jan; 350(1):11-20. PubMed ID: 14702423
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized controlled pilot trial of valacyclovir for attenuating inflammation and immune activation in HIV/herpes simplex virus 2-coinfected adults on suppressive antiretroviral therapy.
    Yi TJ; Walmsley S; Szadkowski L; Raboud J; Rajwans N; Shannon B; Kumar S; Kain KC; Kaul R; Tan DH
    Clin Infect Dis; 2013 Nov; 57(9):1331-8. PubMed ID: 23946220
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High-dose valacyclovir HSV-2 suppression results in greater reduction in plasma HIV-1 levels compared with standard dose acyclovir among HIV-1/HSV-2 coinfected persons: a randomized, crossover trial.
    Mugwanya K; Baeten JM; Mugo NR; Irungu E; Ngure K; Celum C
    J Infect Dis; 2011 Dec; 204(12):1912-7. PubMed ID: 21998479
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Use of acyclovir for suppression of human immunodeficiency virus infection is not associated with genotypic evidence of herpes simplex virus type 2 resistance to acyclovir: analysis of specimens from three phase III trials.
    Watson-Jones D; Wald A; Celum C; Lingappa J; Weiss HA; Changalucha J; Baisley K; Tanton C; Hayes RJ; Marshak JO; Gladden RG; Koelle DM
    J Clin Microbiol; 2010 Oct; 48(10):3496-503. PubMed ID: 20702659
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of daily aciclovir on HIV disease progression in individuals in Rakai, Uganda, co-infected with HIV-1 and herpes simplex virus type 2: a randomised, double-blind placebo-controlled trial.
    Reynolds SJ; Makumbi F; Newell K; Kiwanuka N; Ssebbowa P; Mondo G; Boaz I; Wawer MJ; Gray RH; Serwadda D; Quinn TC
    Lancet Infect Dis; 2012 Jun; 12(6):441-8. PubMed ID: 22433279
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of condoms on reducing the transmission of herpes simplex virus type 2 from men to women.
    Wald A; Langenberg AG; Link K; Izu AE; Ashley R; Warren T; Tyring S; Douglas JM; Corey L
    JAMA; 2001 Jun; 285(24):3100-6. PubMed ID: 11427138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of aciclovir on HIV-1 acquisition in herpes simplex virus 2 seropositive women and men who have sex with men: a randomised, double-blind, placebo-controlled trial.
    Celum C; Wald A; Hughes J; Sanchez J; Reid S; Delany-Moretlwe S; Cowan F; Casapia M; Ortiz A; Fuchs J; Buchbinder S; Koblin B; Zwerski S; Rose S; Wang J; Corey L;
    Lancet; 2008 Jun; 371(9630):2109-19. PubMed ID: 18572080
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Transient Increase in Herpes Simplex Virus Type 2 (HSV-2)-Associated Genital Ulcers Following Initiation of Antiretroviral Therapy in HIV/HSV-2-Coinfected Individuals.
    Fife KH; Mugwanya K; Thomas KK; Baeten JM; Celum C; Bukusi E; de Bruyn G; Mujugira A; Vwalika B; Wald A; Lingappa JR;
    J Infect Dis; 2016 May; 213(10):1573-8. PubMed ID: 26704611
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The cost-effectiveness of herpes simplex virus-2 suppressive therapy with daily aciclovir for delaying HIV disease progression among HIV-1-infected women in South Africa.
    Vickerman P; Devine A; Foss AM; Delany-Moretlwe S; Mayaud P; Meyer-Rath G
    Sex Transm Dis; 2011 May; 38(5):401-9. PubMed ID: 21317689
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of herpes simplex suppression on incidence of HIV among women in Tanzania.
    Watson-Jones D; Weiss HA; Rusizoka M; Changalucha J; Baisley K; Mugeye K; Tanton C; Ross D; Everett D; Clayton T; Balira R; Knight L; Hambleton I; Le Goff J; Belec L; Hayes R; ;
    N Engl J Med; 2008 Apr; 358(15):1560-71. PubMed ID: 18337596
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Herpes simplex virus (HSV) suppression with valacyclovir reduces rectal and blood plasma HIV-1 levels in HIV-1/HSV-2-seropositive men: a randomized, double-blind, placebo-controlled crossover trial.
    Zuckerman RA; Lucchetti A; Whittington WL; Sanchez J; Coombs RW; Zuñiga R; Magaret AS; Wald A; Corey L; Celum C
    J Infect Dis; 2007 Nov; 196(10):1500-8. PubMed ID: 18008230
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of acyclovir on HIV-1 set point among herpes simplex virus type 2-seropositive persons during early HIV-1 infection.
    Kim HN; Wang J; Hughes J; Coombs R; Sanchez J; Reid S; Delany-Moretlwe S; Cowan F; Fuchs J; Eshleman SH; Khaki L; McMahon MA; Siliciano RF; Wald A; Celum C
    J Infect Dis; 2010 Sep; 202(5):734-8. PubMed ID: 20649426
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomised placebo-controlled trial to explore the effect of suppressive therapy with acyclovir on genital shedding of HIV-1 and herpes simplex virus type 2 among Zimbabwean sex workers.
    Cowan FM; Pascoe SJ; Barlow KL; Langhaug LF; Jaffar S; Hargrove JW; Robinson NJ; Bassett MT; Wilson D; Brown DW; Hayes RJ
    Sex Transm Infect; 2008 Dec; 84(7):548-53. PubMed ID: 18684855
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial.
    Celum C; Morrow RA; Donnell D; Hong T; Hendrix CW; Thomas KK; Fife KH; Nakku-Joloba E; Mujugira A; Baeten JM;
    Ann Intern Med; 2014 Jul; 161(1):11-9. PubMed ID: 24979446
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reducing the risk of transmitting genital herpes: advances in understanding and therapy.
    Leone P
    Curr Med Res Opin; 2005 Oct; 21(10):1577-82. PubMed ID: 16238897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tenofovir Gel for Prevention of Herpes Simplex Virus Type 2 Acquisition: Findings From the VOICE Trial.
    Marrazzo JM; Rabe L; Kelly C; Richardson B; Deal C; Schwartz JL; Chirenje ZM; Piper J; Morrow RA; Hendrix CW; Marzinke MA; Hillier SL;
    J Infect Dis; 2019 May; 219(12):1940-1947. PubMed ID: 30753642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.